Blog

Icro Meattini: Breast-Conserving Therapy is safe and effective for BRCA1/2 carriers

Icro Meattini/X

May 6, 2025, 10:05

Icro Meattini: Breast-Conserving Therapy is safe and effective for BRCA1/2 carriers

Icro Meattini, Associate Professor of Radiation Oncology at the University of Florence, shared a post on X:

“Breast-Conserving Therapy is safe & effective for BRCA1/2 carriers—no impact on OS or DMFS.

CBC risk (esp. in BRCA1) supports considering bilateral mastectomy.

Personalised decisions, early BRCA testing & expert counselling are key.”

Icro Meattini emphasized that breast-conserving therapy is a safe and effective option for BRCA1 and BRCA2 carriers, with no effect on overall or distant metastasis-free survival.

He also noted the importance of considering bilateral mastectomy, particularly in BRCA1 cases, and highlighted the role of early BRCA testing and personalized counseling.

More posts featuring Icro Meattini.

BCT bilateral mastectomy BRCA BRCA testing BRCA1/2 carriers cancer fight against cancer Global fight against cancer Icro Meattini OncoDaily Oncology RadOnc University of Florence

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action